U.S. Employers Plan to Drop GLP-1 Drug Coverage, Survey Shows 14% Will Cut Benefits by 2027

About 14% of U.S. employers have already decided or intend to stop covering GLP-1 medicines by 2027, according to a Reuters‑cited Business Group on Health survey. The shift reflects growing concerns over rising health‑care expenses.

Employers cited increasing drug costs as the primary driver for the coverage reductions. The survey suggests that cost pressures are prompting payers to reevaluate benefit designs for weight‑loss and diabetes treatments.

At the same time, two‑thirds of surveyed employers reported a rise in the use of GLP-1 drugs, highlighting a tension between higher utilization and shrinking coverage.

The brief also noted a pending GSK shingles vaccine and a decline in Massachusetts biotech employment, the first drop since 2002.